XTL BIOPHARMACEUTICALS LTD
XTLB · XNASCIK 1023549fmd_01MM8YAVH9KVB307KW0P7D503FManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 14 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | – | – | 0 |
| Cost of revenue | – | – | – | – | – | – | – | – | – | 0 |
| Gross profit | – | – | – | – | – | – | – | – | – | 0 |
| Research and development | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | – | 2 |
| Operating income | (4) | (3) | (1) | (1) | (1) | (1) | (1) | (1) | (1) | (2) |
| Interest expense | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | – | 0 |
| Income before taxes | – | – | – | – | – | – | – | (1) | (2) | (1) |
| Income tax expense | – | – | – | – | – | – | – | – | – | (0) |
| Net income from continuing operations | (4) | (3) | (1) | – | – | – | – | – | – | (1) |
| Net income | 0 | (3) | (1) | 4 | (1) | (3) | 0 | (1) | (2) | (1) |